A Double-Blind, Randomized, Parallel, Comparative Study to Evaluate the Efficacy and Safety of an Antidiabetic Agent Repaglinide for the Treatment of Type 2 Diabetes Mellitus Patients
Phase 4
- Conditions
- Diabetes Mellitus, Type 2
- First Posted Date
- 2006-06-13
- Last Posted Date
- 2006-06-13
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 50
- Registration Number
- NCT00336310
- Locations
- π¨π³
National Cheng-Kung University Hospital, Tainan, Taiwan